Lilly to collaborate with Lycia on novel protein degraders
The collaborators will use Lycia’s lysosomal targeting chimera (LYTAC) protein…
The collaborators will use Lycia’s lysosomal targeting chimera (LYTAC) protein degradation platform to develop therapies for five targets across Lilly’s therapeutic areas of focus.



![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
